CRISPR/Cas‐Powered Biosensing

Mengying Deng,Fengqin Li,Xiaolei Zuo,Min Li
DOI: https://doi.org/10.1002/anse.202200052
2022-08-29
Abstract:CRISPR/Cas system is to be a powerful tool to construct the nucleic acid diagnostic platform. Specific recognition and cleavage of CRISPR/Cas systems enable selective recognition of analytes and physicochemical signal translation of biorecognition events. Given the diversity of Cas effectors, we outline various types of Cas effectors and their associated single‐guide RNA (sgRNA), protospacer adjacent motif (PAM) sequence, or protospacer flanking sequence (PFS), as well as the characteristics of the CRISPR/Cas complex in nucleic acid detection. In light of this, we discuss the coupling of CRISPR/Cas systems to various biosensing strategies (e.g., amplification strategy, electronic methods, or optical methods) and point‐of‐care testing (POCT) (e.g., paper‐based lateral flow assays, field‐effect transistor, microfluidics devices, and solid‐state nanopore sensors) that could enable the specificity and sensitivity of the diagnostic platform for biosensing applications. Additionally, we also discuss the new frontiers and the challenges to be addressed in this field.
What problem does this paper attempt to address?